FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281714176> ?p ?o ?g. }

• W4281714176 endingPage "3503" @default.
• W4281714176 startingPage "3503" @default.
• W4281714176 abstract "3503 Background: Continuous anti-EGFR-based FOLFIRI is a first-line standard of care in pts with RAS/BRAF wt mCRC. The emergence of resistance and treatment-related toxicity limit the efficacy of continuous treatment. Thus, an intermittent strategy could reduce both toxicity and resistance. Methods: This is a prospective, randomized, non-comparative, open-label, multicenter phase II study. Unresectable, previously untreated RAS/BRAF wt mCRC pts, were randomized to a control arm (A) receiving FOLFIRI/PANI continuously until progression or to the experimental arm (B), receiving 8 cycles of the same regimen followed by a treatment free interval. This lasted untill progressive disease, when another treatment period of up to 8 cycles was restarted. This intermittent strategy was continued until progression occurred on treatment. Tumor assessment was always done every 8 weeks in both arms. Pts were stratified for center, ECOG PS (0-1 vs 2), previous adjuvant therapy (yes or no), sidedness (right vs left) and metastatic sites (1 vs ≥ 2). The primary endpoint was the progression-free survival on treatment (PFSOT) at 1 year. Assuming p1=43% PFSOT at 1 year, corresponding to an expected median PFSOT time ≥ 10 months in the experimental arm, and a 5% drop-out rate, a sample size of 68 pts in each arm granted the study a power of 80%, with a type I error of 10% (binomial test) for rejecting the null hypothesis, p0=30%, corresponding to a median PFSOT time of ≤ 7 months. Secondary endpoints were safety, quality of life, OS and response rate (ORR); ctDNA samples were also collected. No formal comparison between the two arms was planned. Results: From May 2018 to June 2021, 137 pts were randomized (69 arm A/68 arm B). Main pts’ characteristics were (arm A/B): males 59/61%; median age 62/66yrs; PS 0 84/72%; right colon 17/15%; previous adjuvant therapy 22/29%; single metastatic site 33/26%. At a median follow-up of 18 months (IQR: 10-26), median PFS OT was 12.6 months (95% CI: 9.0-16.1) in arm A and 17.6 months (95% CI: 7.5-27.8) in arm B with a 1 year PFSOT rate of 51.7% and 61.3%, respectively. ORR (arm A/B) was 64/56%. Median number of FOLFIRI/PANI cycles administered per patient were (arm A/B) 13/12. Main grade 3-4 toxicities were (arm A/B): skin 27/13%, neutropenia 23/22%; diarrhea 13/15%. Conclusions: The primary endpoint of the study was met with the intermittent FOLFIRI-PANI strategy producing a long PFS with a reduced skin toxicity. These data deserve further investigations in a phase III trial. Clinical trial information: NCT04425239." @default.
• W4281714176 created "2022-06-13" @default.
• W4281714176 creator A5008674075 @default.
• W4281714176 creator A5011308487 @default.
• W4281714176 creator A5012951315 @default.
• W4281714176 creator A5014792832 @default.
• W4281714176 creator A5018105976 @default.
• W4281714176 creator A5018958639 @default.
• W4281714176 creator A5019332793 @default.
• W4281714176 creator A5023654061 @default.
• W4281714176 creator A5031075647 @default.
• W4281714176 creator A5032330087 @default.
• W4281714176 creator A5038665049 @default.
• W4281714176 creator A5062538462 @default.
• W4281714176 creator A5066976468 @default.
• W4281714176 creator A5067997872 @default.
• W4281714176 creator A5071355854 @default.
• W4281714176 creator A5074752423 @default.
• W4281714176 creator A5085152226 @default.
• W4281714176 creator A5086743021 @default.
• W4281714176 creator A5088304855 @default.
• W4281714176 creator A5091765229 @default.
• W4281714176 date "2022-06-01" @default.
• W4281714176 modified "2023-10-16" @default.
• W4281714176 title "Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study." @default.
• W4281714176 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3503" @default.
• W4281714176 hasPublicationYear "2022" @default.
• W4281714176 type Work @default.
• W4281714176 citedByCount "7" @default.
• W4281714176 countsByYear W42817141762022 @default.
• W4281714176 countsByYear W42817141762023 @default.
• W4281714176 crossrefType "journal-article" @default.
• W4281714176 hasAuthorship W4281714176A5008674075 @default.
• W4281714176 hasAuthorship W4281714176A5011308487 @default.
• W4281714176 hasAuthorship W4281714176A5012951315 @default.
• W4281714176 hasAuthorship W4281714176A5014792832 @default.
• W4281714176 hasAuthorship W4281714176A5018105976 @default.
• W4281714176 hasAuthorship W4281714176A5018958639 @default.
• W4281714176 hasAuthorship W4281714176A5019332793 @default.
• W4281714176 hasAuthorship W4281714176A5023654061 @default.
• W4281714176 hasAuthorship W4281714176A5031075647 @default.
• W4281714176 hasAuthorship W4281714176A5032330087 @default.
• W4281714176 hasAuthorship W4281714176A5038665049 @default.
• W4281714176 hasAuthorship W4281714176A5062538462 @default.
• W4281714176 hasAuthorship W4281714176A5066976468 @default.
• W4281714176 hasAuthorship W4281714176A5067997872 @default.
• W4281714176 hasAuthorship W4281714176A5071355854 @default.
• W4281714176 hasAuthorship W4281714176A5074752423 @default.
• W4281714176 hasAuthorship W4281714176A5085152226 @default.
• W4281714176 hasAuthorship W4281714176A5086743021 @default.
• W4281714176 hasAuthorship W4281714176A5088304855 @default.
• W4281714176 hasAuthorship W4281714176A5091765229 @default.
• W4281714176 hasConcept C121608353 @default.
• W4281714176 hasConcept C126322002 @default.
• W4281714176 hasConcept C141071460 @default.
• W4281714176 hasConcept C143998085 @default.
• W4281714176 hasConcept C168563851 @default.
• W4281714176 hasConcept C203092338 @default.
• W4281714176 hasConcept C2776694085 @default.
• W4281714176 hasConcept C2776705615 @default.
• W4281714176 hasConcept C2778332735 @default.
• W4281714176 hasConcept C2779998722 @default.
• W4281714176 hasConcept C2780259306 @default.
• W4281714176 hasConcept C2780739268 @default.
• W4281714176 hasConcept C2781413609 @default.
• W4281714176 hasConcept C29730261 @default.
• W4281714176 hasConcept C31760486 @default.
• W4281714176 hasConcept C526805850 @default.
• W4281714176 hasConcept C71924100 @default.
• W4281714176 hasConcept C90924648 @default.
• W4281714176 hasConceptScore W4281714176C121608353 @default.
• W4281714176 hasConceptScore W4281714176C126322002 @default.
• W4281714176 hasConceptScore W4281714176C141071460 @default.
• W4281714176 hasConceptScore W4281714176C143998085 @default.
• W4281714176 hasConceptScore W4281714176C168563851 @default.
• W4281714176 hasConceptScore W4281714176C203092338 @default.
• W4281714176 hasConceptScore W4281714176C2776694085 @default.
• W4281714176 hasConceptScore W4281714176C2776705615 @default.
• W4281714176 hasConceptScore W4281714176C2778332735 @default.
• W4281714176 hasConceptScore W4281714176C2779998722 @default.
• W4281714176 hasConceptScore W4281714176C2780259306 @default.
• W4281714176 hasConceptScore W4281714176C2780739268 @default.
• W4281714176 hasConceptScore W4281714176C2781413609 @default.
• W4281714176 hasConceptScore W4281714176C29730261 @default.
• W4281714176 hasConceptScore W4281714176C31760486 @default.
• W4281714176 hasConceptScore W4281714176C526805850 @default.
• W4281714176 hasConceptScore W4281714176C71924100 @default.
• W4281714176 hasConceptScore W4281714176C90924648 @default.
• W4281714176 hasIssue "16_suppl" @default.
• W4281714176 hasLocation W42817141761 @default.
• W4281714176 hasOpenAccess W4281714176 @default.
• W4281714176 hasPrimaryLocation W42817141761 @default.
• W4281714176 hasRelatedWork W1225528904 @default.
• W4281714176 hasRelatedWork W1968430623 @default.
• W4281714176 hasRelatedWork W2058934913 @default.
• W4281714176 hasRelatedWork W2088713834 @default.
• W4281714176 hasRelatedWork W2158997283 @default.
• W4281714176 hasRelatedWork W2593180677 @default.

• next